Therapy using a combination of raloxifene and alendronate

Details Therapy using a combination of raloxifene and alendronate Therapy using a combination of raloxifene and alendronate

2005-02-18

2009-08-25

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S108000, C514S114000, C514S320000

Reexamination Certificate

active

07579333

ABSTRACT:
Provided are methods of treating bone disease including, but not limited to, osteoporosis, metastatic bone disease, or Paget's disease, by administering a combination of raloxifene and alendronate in a manner that mitigates the formation of ulcerative adverse events.

REFERENCES:
patent: 2001/0051636 (2001-12-01), Black et al.
patent: 2003/0206954 (2003-11-01), Lerner et al.
patent: 2003/0216358 (2003-11-01), Muchmore et al.
patent: 2004/0052843 (2004-03-01), Lerner et al.
patent: WO 01/28564 (2001-04-01), None
PDR (Physician Desk Reference, http://www.thomsonhc.com.librarian) for Evista tablets).
PDR (Physician Desk Reference, http://www.thomsonhc.com.librarian) for Fosamax tablets.
Rocaltrol Oral Solution, Physician's Desk Reference, pp. 2914-2916 (57th Ed., 2003).
Fosamax®, (Alendronate Sodium Tablets) Physician's Desk References, pp. 1996-2003 (57th Ed., 2003).
Evista®, (Raloxefine Hydrochloride) Physician's Desk Reference, pp. 1717-1721 (55th Ed., 2001).
S.C. Abraham et al., “Alendronate-Associated Esophageal Injury: Pathologic And Endoscopic Features”Modern Pathology, vol. 12(12), pp. 1152-1157, (1999).
D.Y. Graham et al., “Alendronate gastric ulcers”Aliment Pharmacol. Ther., vol. 13(4), pp. 515-519, (1999).
J.K. Marshall et al., “A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract”Aliment Pharmacol. Ther.vol. 14(11), pp. 1451-1457, (2000).
F.L. Lanza et al., “Placebo-controlled randomized evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy post-menopausal women”Aliment Pharmacol. Ther., vol. 14(12), pp. 1663-1670 (2000).
A.B. Thomson et al., “14-day Endoscopy Study Comparing Risedronate and Alendronate in Post-menopausal Women Stratified byHelicobacter pyloriStatus”J. Rheumatol., vol. 29(9), pp. 1965-1974 (2002).
F. Lanza et al, “Etodolac Compared with Aspirin: An Endoscopic Study of the Gastrointestinal Tracts of Normal Volunteers”J. Rheumatol., vol. 13, pp. 299-303 (1986).
S.N. Elliott et al., “Alendronate Induces Gastric Injury And Delays Ulcer Healing In Rodents”Life Sciences, vol. 62(1), pp. 77-91, (1998).
B. J. Gertz et al., “Studies of the oral bioavailability of alendronate”Clinical Pharmacology&Therapeutics, vol. 58(3), pp. 288-298, (1995).
U.A. Liberman et al., “Esophagitis and Alendronate”N. Engl. J. Med., vol. 335(8), pp. 1069-1070, (1996).
D.C. Bauer et al., “Upper Gastrointestinal Tract Safety Profile of Alendronate: The Fracture Intervention Trial”Arch. Intern. Med., vol. 160(4), pp. 517-525, (2000).
D. J. Hetzel et al., “Healing and Relapse of Severe Peptic Esophagitis after Treatment with Omeprazole”Gastroenterology, vol. 95, pp. 903-912, (1988).
F.L. Lanza et al., “Endoscopic Comparison of Esophageal and Gastroduodenal Effects of Risedronate and Alendronate in Postmenopausal Women”Gastroentorology, vol. 119, pp. 631-638, (2000).
R. E. Colina et al., “A New Probable Increasing Cause Of Esophageal Ulceration: Alendronate”Am. J. Gastroenterology, vol. 92(4), pp. 704-706, (1997).
D.Y. Graham, “Excess Gastric Ulcers Are Associated With Alendronate Therapy”Am. J. Gastroenterology, vol. 93(8), pp. 1395-1396, (1998).
D. Jaspersen, “Drug-Induced Oesophageal Disorders: Pathogenesis, Incidence, Prevention And Management,”Drug Safety, vol. 22(3), pp. 237-249, (2000).
S. J. Smith et al., “Pill-Induced Esophagitis Caused By Oral Rifampin”Ann. Pharmocother., vol. 33(1), pp. 27-31, (1999).
J. W. Kikendall, “Pill Esophagitis”J. Clin. Gastroenterol., vol. 28(4), pp. 298-305, (1999).
J. H. Lin, “Bisphosphonates: A Review of Their Pharmacokinetic Properties”Bone, vol. 18 (2), pp. 75-85, (1996).
A. G. Porras et al., “Pharmacokinetics of Alendronate”Clin. Pharmacokinet., vol. 36, pp. 315-328, (1999).
M. Kleerekoper et al., “Comparative Safety of Bone Remodeling Agents with A Focus on Osteoporosis Therapies”J. Clin. Pharmacol., vol. 41, pp. 239-250, (2001).
A. Cannigia et al., “Effects of 1,25-Dihydroxycholecalciferol on Calcium Absorption in Postmenopausal Osteoporosis”Clinical Endocrinology, vol. 11, pp. 99-103, (1979).
B. L. Riggs et al., “Effect of Long Term Treatment with Calcitriol on Calcium Absorption and Mineral Metabolism in Postmenopausal Osteoporosis”J. Clin. Endocrinol. Meta., vol. 61(3), pp. 457-461, (1985).
I. R. Reid et al., “Long Term Effects of Calcium Supplementation on Bone Loss and Fracture in Post-menopausal Women: A Randomized Controlled Trial”Am. J. Med., vol. 98(4), pp. 331-335, (1995).
Calcitrol, Merck Index pp. 1681-1682 (12th Ed. 1996).
T. Masud et al., “Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women”Ann. Rheum. Diseases, vol. 57, pp. 346-349, (1998).
N. Malvolta et al., “Calcitriol and Alendronate Combination Treatment in Menopausal Women with Low Bone Mass”Int. J. Tissue React., vol. XXI(2), pp. 51-59, (1999).
B. Frediani et al., “Effects Of Combined Treatment With Calcitriol Plus Alendronate On Bone Mass And Bone Turnover In Postmenopausal Osteoporosis-Two Years Of Continuous Treatment”Clin. Drug Invest., vol. 15(3), pp. 235-244, (1998).
R. Nuti et al., “Effect of Treatment with Calcitriol Combined with Low-dosage Alendronate in Involutional Osteoporosis,”Clin. Drug Invest., vol. 19(1), pp. 55-61, (2000).
O. Johnell O. et al., “Effects Of Raloxifene (RLX), Alendronate (ALN) And RLX+ALN On Bone Mineral Density (BMD) And Biochemical Markers Of Bone Turnover In Postmenopausal Women With Osteoporosis”Journal of Bone and mineral Research, vol. 14, pp. S157, 1100, (1999).
O. Johnell et al., “Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal women with Osteoporosis”J. Clin. Endocrinol. Metab., vol. 87(3), pp. 985-992, (2002).
P. Burckhardt, “Selective Estrogen Receptor Modulators (SERM): neue Substanzen für die Hormonersatztherapie”Schweizerische Medizinische Wochenschrift, vol. 129, pp. 1926-1930, (1999).
N. B. Watts, “Treatment of Osteoporosis with Bisphosphonates”Osteoporosis, vol. 27 (1), pp. 197-214, (2001).
Patent Abstract, Database EPODOC, NZ 27260895A, May 26, 2000 (US equivalent 2001/0051636).

Affiliated with

Also associated with

Rating

Therapy using a combination of raloxifene and alendronate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy using a combination of raloxifene and alendronate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy using a combination of raloxifene and alendronate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4069115